✦ LIBER ✦

1401 THE FGFR3 MUTATION IDENTIFIES PATIENTS WITH FAVORABLE DISEASE AT RADICAL CYSTECTOMY FOR BLADDER CANCER

✍ Scribed by van Rhijn, Bas W.; Bostrom, Peter J.; Shariat, Shahrokh F.; Finelli, Antonio; Sagalowsky, Arthur I.; Fleshner, Neil E.; Bapat, Bharati; Kortekangas, Hannes; Ashfaq, Raheela; Mirtti, Tuomas; Jewett, Michael A.; Lotan, Yair; van der Kwast, Theo H.; Zlotta, Alexandre R.

Book ID: 123332662
Publisher: Lippincott Williams and Wilkins
Year: 2011
Tongue: English
Weight: 95 KB
Volume: 185
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2011.02.1292

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

765 THE FGFR3 MUTATION IDENTIFIES PATIEN

765 THE FGFR3 MUTATION IDENTIFIES PATIENTS WITH FAVORABLE DISEASE AT RADICAL CYSTECTOMY FOR BLADDER CANCER

✍ B.W.G. Van Rhijn; P.J. Bostrom; S.F. Shariat; A. Finelli; A.I. Sagalowsky; N.E. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 176 KB

1401 IS THE NODAL YIELD ASSOCIATED WITH

1401 IS THE NODAL YIELD ASSOCIATED WITH OUTCOMES IN BLADDER CANCER PATIENTS WITHOUT NODAL METASTASIS AT RADICAL CYSTECTOMY?

✍ Rink, Michael; Shariat, Shahrokh F.; Green, David; Cha, Eugene K.; Hansen, Jens; 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 51 KB

603 FGFR3 PROTEIN OVER-EXPRESSION IN THE

603 FGFR3 PROTEIN OVER-EXPRESSION IN THE ABSENCE OF A FGFR3 MUTATION IS NOT ASSOCIATED WITH FAVORABLE DISEASE CHARACTERISTICS IN BLADDER CANCER

✍ Rhijn B.W.G. Van; B. Bapat; L. Liyang; P.J. Bostrom; N.E. Fleshner; M.A.S. Jewet 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 176 KB

Disease-Free Survival at 2 or 3 Years Co

Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer

✍ Sonpavde, Guru; Khan, Myrna M.; Lerner, Seth P.; Svatek, Robert S.; Novara, Giac 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 260 KB

530 EXTERNAL VALIDATION OF DISEASE-FREE

530 EXTERNAL VALIDATION OF DISEASE-FREE SURVIVAL AT 2 OR 3 YEARS AS A SURROGATE AND NEW PRIMARY ENDPOINT FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR MUSCLE INVASIVE UROTHELIAL CANCER OF THE BLADDER

✍ Bastian, Patrick J.; May, Matthias; Fritsche, Hans-Martin; Buchner, Alexander; B 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 179 KB

External validation of disease-free surv

External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder

✍ P. Nuhn; M. May; H.-M. Fritsche; A. Buchner; S. Brookman-May; C. Bolenz; R. Mori 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 336 KB